^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYC expression

    i
    Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
    Entrez ID:
    4609
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Study of Oral MRT-2359 in Selected Cancer Patients (MRT-2359-001) (NCT05546268)
    Phase 1/2
    Monte Rosa Therapeutics, Inc
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/12/2022
    Primary completion :
    05/01/2026
    Completion :
    11/01/2027
    MYC • MYCN
    |
    MYCN amplification • MYC expression
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (A051701) (NCT03984448)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/22/2019
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (NCT03742258)
    Phase 1
    Northwestern University
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/13/2019
    Primary completion :
    03/12/2021
    Completion :
    12/19/2028
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    FOG-001 in Locally Advanced or Metastatic Solid Tumors (FOG-001-101) (NCT05919264)
    Phase 1/2
    Fog Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/19/2023
    Primary completion :
    04/01/2027
    Completion :
    08/31/2027
    MSI • CTNNB1
    |
    MYC expression
    |
    FOG-001
    A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma (GO43075) (NCT04980222)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    03/22/2022
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    MYC • BCL2 • CD20 • BCL6
    |
    CD20 positive • MYC expression • BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous
    Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma (NCT06357338)
    Phase N/A
    Marwa Mahmoud Hassan
    Enrolling by invitation
    Last update posted :
    04/10/2024
    Initiation :
    03/19/2024
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    MYC
    |
    MYC expression
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (NCT04479267)
    Phase 2
    Barbara Ann Karmanos Cancer Institute
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    08/21/2020
    Primary completion :
    11/15/2025
    Completion :
    11/15/2026
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone
    A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma (NCT05358379)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    04/14/2022
    Primary completion :
    08/01/2025
    Completion :
    11/01/2025
    PLK1 • CDKN1A
    |
    MYC expression
    CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) (NCT03287817)
    Phase 1/2
    Autolus Limited
    Completed
    Last update posted :
    01/08/2024
    Initiation :
    09/05/2017
    Primary completion :
    12/06/2023
    Completion :
    12/06/2023
    MYC • BCL2 • BCL6
    |
    MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    Keytruda (pembrolizumab) • cyclophosphamide • AUTO3
    Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087)
    Phase 1
    Lapo Alinari
    Recruiting
    Last update posted :
    12/29/2023
    Initiation :
    03/06/2023
    Primary completion :
    03/05/2027
    Completion :
    03/05/2027
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation
    |
    tegavivint (BC2059)
    R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04214626)
    Phase 2
    Henan Cancer Hospital
    Active, not recruiting
    Last update posted :
    12/05/2023
    Initiation :
    01/02/2020
    Primary completion :
    11/29/2023
    Completion :
    01/02/2025
    MYC • BCL2
    |
    BCL2 expression • MYC expression • TP53 expression
    |
    Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • vincristine • prednisone • cyclophosphamide intravenous
    Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956)
    Phase 1
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    10/30/2023
    Initiation :
    06/15/2020
    Primary completion :
    05/15/2026
    Completion :
    05/15/2027
    MYC • BCL2 • CD20 • BCL6
    |
    BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer (VNC-152-101) (NCT02635672)
    Phase 1
    Vincerx Pharma, Inc.
    Active, not recruiting
    Last update posted :
    08/16/2023
    Initiation :
    02/10/2016
    Primary completion :
    12/30/2024
    Completion :
    12/30/2024
    MYC
    |
    MYC amplification • MYC expression
    |
    Keytruda (pembrolizumab) • enitociclib (VIP152)
    Study of E7777 Prior to Kymriah for R/R DLBCL (NCT04855253)
    Phase 1/2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    06/09/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    MYC
    |
    MYC expression
    |
    Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
    Gallium-68 Citrate PET Used in Prostate Cancer (NCT02391025)
    Phase 1
    Rahul Aggarwal
    Completed
    Last update posted :
    06/19/2023
    Initiation :
    05/28/2015
    Primary completion :
    06/15/2023
    Completion :
    06/15/2023
    MYC
    |
    MYC expression
    Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04668365)
    Phase 2
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    05/18/2023
    Initiation :
    12/25/2020
    Primary completion :
    12/25/2023
    Completion :
    12/25/2025
    MYC • BCL2 • CD79B • CD79A
    |
    BCL2 expression • MYC expression
    |
    carboplatin • Rituxan (rituximab) • cytarabine • cyclophosphamide • oxaliplatin • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone • cyclophosphamide intravenous
    A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy (NCT05527912)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    04/25/2023
    Initiation :
    02/24/2023
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    MYC • BCL2
    |
    BCL2 expression • MYC expression
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    Clinical Trial of WB100 on Advanced Solid Tumor (NCT05100251)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    01/26/2023
    Initiation :
    10/25/2021
    Primary completion :
    10/25/2023
    Completion :
    10/25/2023
    MYC • CA 19-9
    |
    MYC overexpression • MYC expression • MYC positive
    |
    WB100
    Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission (NCT05596097)
    Phase 2
    LanZhou University
    Not yet recruiting
    Last update posted :
    10/27/2022
    Initiation :
    10/30/2022
    Primary completion :
    10/20/2024
    Completion :
    07/30/2026
    TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A
    |
    BCL2 expression • MYC expression
    |
    Brukinsa (zanubrutinib)
    A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART) (NCT02633098)
    Phase 2
    St George's, University of London
    Recruiting
    Last update posted :
    10/12/2022
    Initiation :
    04/26/2017
    Primary completion :
    12/31/2022
    Completion :
    10/31/2025
    KRAS • BRAF • MYC • CCND1 • CD31 • PECAM1
    |
    KRAS mutation • BRAF mutation • MYC expression • CCND1 expression
    SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression (NCT05498636)
    Phase 1/2
    The Affiliated Hospital of Qingdao University
    Not yet recruiting
    Last update posted :
    08/19/2022
    Initiation :
    10/01/2022
    Primary completion :
    07/30/2025
    Completion :
    12/31/2025
    MYC • BCL2
    |
    MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement
    |
    lenalidomide • etoposide IV • Xpovio (selinexor) • prednisone
    A Study of WJ05129 in Advanced Malignant Solid Tumors (NCT05326035)
    Phase 1/2
    Suzhou Junjing BioSciences Co., Ltd.
    Not yet recruiting
    Last update posted :
    04/13/2022
    Initiation :
    04/30/2022
    Primary completion :
    03/31/2023
    Completion :
    06/30/2024
    MYC
    |
    MYC expression • RB1 negative
    |
    WJ05129
    Cemiplimab for Secondary Angiosarcomas (CEMangio) (NCT04873375)
    Phase 2
    Radboud University
    Recruiting
    Last update posted :
    02/03/2022
    Initiation :
    01/01/2022
    Primary completion :
    07/01/2024
    Completion :
    10/01/2025
    PD-L1 • TMB
    |
    PD-L1 expression • MYC expression
    |
    Libtayo (cemiplimab-rwlc)
    DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma (NCT03837873)
    Phase 2
    Institute of Hematology & Blood Diseases Hospital
    Recruiting
    Last update posted :
    01/26/2022
    Initiation :
    01/21/2019
    Primary completion :
    09/01/2023
    Completion :
    09/01/2024
    BCL2 • BCL6 • CD5
    |
    BCL2 expression • MYC expression • BCL6 rearrangement • BCL2 rearrangement
    |
    cisplatin • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • cyclophosphamide intravenous
    A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (NCT03255096)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    01/24/2022
    Initiation :
    08/28/2017
    Primary completion :
    07/03/2019
    Completion :
    07/03/2019
    MYC • BCL2
    |
    BCL2 expression • MYC expression
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • RG6146
    R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study (NCT04842487)
    Phase 2
    Sun Yat-sen University
    Not yet recruiting
    Last update posted :
    04/13/2021
    Initiation :
    04/10/2021
    Primary completion :
    12/30/2023
    Completion :
    12/30/2023
    MYC • BCL2
    |
    BCL2 expression • MYC expression
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • cyclophosphamide intravenous
    Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids (TAILOR) (NCT04555473)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    09/18/2020
    Initiation :
    05/12/2020
    Primary completion :
    11/04/2021
    Completion :
    05/04/2023
    BRCA1 • MYC
    |
    MYC overexpression • MYC expression
    A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (CAVALLI) (NCT02055820)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    06/11/2020
    Initiation :
    11/17/2013
    Primary completion :
    06/28/2017
    Completion :
    06/28/2019
    CD20
    |
    CD20 positive • MYC expression
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • cyclophosphamide intravenous
    Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831 (NCT00898898)
    Phase N/A
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    07/02/2019
    Initiation :
    05/01/2000
    Primary completion :
    01/01/2010
    Completion :
    04/01/2019
    HER-2 • MYC • PTEN • TOP2A
    |
    HER-2 positive • MYC expression • TOP2A amplification
    A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies (NCT01987362)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    01/05/2018
    Initiation :
    10/16/2013
    Primary completion :
    10/11/2017
    Completion :
    10/11/2017
    MYC • NUTM1
    |
    MYC expression
    |
    RG6146
    Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer (NCT01938638)
    Phase 1
    Bayer
    Completed
    Last update posted :
    10/20/2017
    Initiation :
    09/26/2013
    Primary completion :
    08/17/2016
    Completion :
    09/19/2016
    MYC • PCNA
    |
    MYC expression • PCNA expression
    |
    atuveciclib (BAY 1143572)
    IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia (NCT01701310)
    Phase 4
    Nottingham University Hospitals NHS Trust
    Completed
    Last update posted :
    10/28/2016
    Initiation :
    04/01/2012
    Primary completion :
    12/01/2014
    Completion :
    12/01/2014
    MYC
    |
    MYC expression